Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing–remitting multiple sclerosis patients

Background and objectivesMultiple sclerosis (MS) is a chronic, progressive neurological disease characterized by early-stage neuroinflammation, neurodegeneration, and demyelination that involves a spectrum of heterogeneous clinical manifestations in terms of disease course and response to therapy. E...

Description complète

Détails bibliographiques

Auteurs principaux:	Ivan Arisi, Leonardo Malimpensa, Valeria Manzini, Rossella Brandi, Tommaso Gosetti di Sturmeck, Chiara D’Amelio, Sebastiano Crisafulli, Gina Ferrazzano, Daniele Belvisi, Francesca Malerba, Rita Florio, Esterina Pascale, Hermona Soreq, Marco Salvetti, Antonino Cattaneo, Mara D’Onofrio, Antonella Conte
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2023-12-01
Collection:	Frontiers in Immunology
Sujets:	multiple sclerosis cladribine ocrelizumab DMT biomarker miRNA
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1234869/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!